Fast Market Research

Just Published: "Global Hyperphosphatemia Drugs Market 2015-2019"

Fast Market Research announces the availability of the new TechNavio report, "Global Hyperphosphatemia Drugs Market 2015-2019", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 08/21/2015 -- Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

Get More Details on this Report and a Full Table of Contents at Global Hyperphosphatemia Drugs Market 2015-2019

Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

Commenting on the report, an analyst from Technavio's team said: "The market presents huge growth opportunities for vendors because of the growing incidence of hyperphosphatemia and associated high pill burden. Currently, many companies are investing in the discovery and R&D of drugs for the condition. For instance, Tenapor by Ardelyx and AstraZeneca is in phase II developmental stage. The entry of this drug will likely reduce the pill burden associated with the condition. Similarly, RDX002, a type 2a sodium phosphate cotransporter (NaP2b) inhibitor, is being developed by Sanofi. Ardelyx licensed the drug to Sanofi, but retained its co-promotion rights in the US. The launch of novel drug candidates with higher efficacy and safety profile, currently under different stages of development, will contribute to market growth."

According to the report, diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The USRDS reported in 2014 that 13.6% adults in the US had CKD, of which diabetes accounted for 44% of kidney failure cases. It also reported in 2012 that high blood pressure led to an increase of 7.7% of kidney failure cases from 2000 to 2010. The International Diabetes Federation reported in 2014 that 387 million people had diabetes in the same year, which is expected to increase by 2035. WHO reported in 2013 that currently over 1 billion people have high blood pressure and about 9.4 million people die from the condition annually worldwide.

Further, the report states that non-adherence to treatment regimens is a major challenge faced by the market.

The key players in the Global Hyperphosphatemia Drugs Market are Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire and Vifor Pharma while other prominent vendors include Alkem, Amgen, Ardelyx, AstraZeneca, Baxter, Bayer, Chugai Pharmaceutical, Japan Tobacco, Kissei Pharmaceutical, Kyowa Hakko Kirin, Mylan, Natco, Novartis, Opko Health, Panion & BF Biotech, Roxane Laboratories, Sandoz, Synthon and Torri Pharmaceutical

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Global Fibromyalgia Drugs Market 2015-2019
- Global Colorectal Cancer Drugs Market 2015-2019
- Global Gastrointestinal OTC Drugs Market 2015-2019
- Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019
- Global Osteoporosis Drugs Market 2015-2019